Search the Newsreel

Projeções de Resultados: Quanta Services Inc (PWR) — LPA e Crescimento de Receita

Advantage Energy (TSE:AAV) Shares Pass Above 200-Day Moving Average - What's Next?

AEP Plantations Tightens Free Float With Ongoing Share Buyback

Enanta Pharma misses Q3 estimates on lower royalty revenue

Enanta Pharmaceuticals missed its Q3 earnings and revenue estimates, reporting an adjusted EPS of -$0.67 against an expected -$0.50, and revenue of $14.4 million, short of the $17.4 million forecast. The shortfall was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus …

AEP Plantations Plc (AEPL.XC) stock price, news, quote and history

Advantage Energy (TSX:AAV) On Glacier Phase 2 And Q2 Results With An Undervalued View

Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026

Enanta Pharmaceuticals announced its financial results for the fiscal third quarter ended June 30, 2026. The report details the company's financial performance during this period.

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline

Enanta Pharmaceuticals reported a net loss of $19.5 million for Q3 FY26, with revenue dropping 21% year-over-year to $14.4 million, missing analyst estimates. Despite financial setbacks, the company advanced its RSV pipeline, initiating the LOTUS pediatric trial and preparing for the RESOLVE adult trial. …

LifeVantage CEO, director Terrence Moorehead files initial beneficial ownership statement

LifeVantage CEO and director Terrence Moorehead has filed an initial Form 3, formally identifying him as the company's president, CEO, and director. This news brief was generated by AI based on original content published by LifeVantage Corporation via EDGAR on August 10, 2026.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) reported a Q3 loss of $0.67 per share, significantly missing the Zacks Consensus Estimate of a $0.37 loss, and its revenues of $14.36 million also fell short of expectations. Despite exceeding EPS estimates three times in the last four quarters, the …

Quanta Services Posted a Record Quarter and a $53 Billion Backlog. Why Is the Stock Cheaper Than in May?

Quanta Services (PWR) experienced a significant stock drop before its Q2 report due to investor concerns, but then saw a double-digit jump after announcing record Q2 results, including a 41% revenue increase, 71% adjusted EPS climb, and a $53 billion backlog. Despite the recovery, …

First Advantage (FA) Stock May Be Below Fair Value After Raised Guidance

First Advantage (FA) stock has seen a significant return over three years, but its valuation signals are mixed. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued, indicating the market is valuing it below its potential cash flows. However, using the Price-to-Sales …

Lifevantage Corp (LFVN) grants CEO Terrence Moorehead 848,765 stock and PRSU units

Lifevantage Corp (LFVN) granted its President and CEO, Terrence Moorehead, equity awards totaling 848,765 units on August 6, 2026. This includes 308,642 shares of common stock as a stock unit award, vesting in three equal installments from 2027 to 2029, and 540,123 Performance Restricted …

First Advantage Announces Launch of Secondary Offering of Common Stock

First Advantage Corporation ATLANTA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation ("First Advantage") (NASDAQ: FA), a global software and data company providing comprehensive, end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring, today announced that …

Silver Lake Funds Plan to Sell 12.5M First Advantage Shares

Investment funds associated with Silver Lake Group intend to sell 12.5 million common shares of First Advantage (NASDAQ: FA) in an underwritten secondary offering. First Advantage will not sell any shares or receive any proceeds from this sale; all proceeds will go to the …

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com

Enanta Pharmaceuticals reported third-quarter results that fell short of analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, missing estimates of -$0.50 and $17.4 million, respectively. This underperformance was primarily due to lower royalty revenue from AbbVie’s hepatitis C …

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss

Enanta Pharmaceuticals reported a 21.6% decline in fiscal Q3 2026 revenue to $14.4 million due to lower MAVYRET/MAVIRET royalties. Despite narrowed operating losses from reduced clinical trial spending, the net loss widened to $19.5 million because of increased royalty-related interest expenses. The company holds …

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) reported a quarterly loss of $0.67 per share, missing analyst estimates by $0.16. The biotechnology company also showed negative return on equity and net margin. Despite the earnings miss, the stock rose 0.3% during Monday trading, and institutional investors hold a …

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M

Enanta Pharmaceuticals reported a Q3 fiscal year loss of $19.5 million on revenue of $14.4 million, with $211.5 million in cash and marketable securities. The company expects current resources to fund operations into fiscal 2029 and highlighted progress in its virology and immunology programs, …

Santander Plans Share Buyback of Up to $2.1 Billion

Banco Santander (SAN) plans to initiate a share buyback program totaling up to 1.825 billion euros ($2.11 billion) to reduce its share capital. This program could involve repurchasing up to 1.47 billion shares, with the start date set for August 24 and continuing until …

Quanta Services Inc. stock outperforms competitors despite losses on the day

Shares of Quanta Services Inc. (PWR) fell 1.64% to $660.86 on Monday, performing better than the overall market decline where the S&P 500 Index (SPX) dropped 0.06% and the Dow Jones Industrial Average (DJIA) fell 0.11%. Despite the daily loss, the company's stock still …

Banco Santander (SAN) sets EUR 1.83B buyback tied to H1 2026 profit

REG - Banco Santander S.A. - Commencement of a program to repurchase own shares

Banco Santander, S.A. (SAN) announced the commencement of a share repurchase program worth EUR 1,825 million, which is approximately 25% of the Group's underlying profit in the first half of 2026. This program aligns with the bank's shareholder remuneration policy, targeting 50% of underlying …

Why Novanta (NOVT) Is Up 16.7% After Q2 Results And Its Largest Medical Acquisition

Novanta Inc. (NOVT) reported strong Q2 2026 results, with sales of US$265.81 million and net income of US$12.54 million, leading to a 16.7% stock increase. The company's largest acquisition to date, Riverpoint Medical, significantly expands its medical market presence and recurring consumables business. This …

Santacruz Silver Mining Ltd. Revenue Breakdown – LSX:A41S50

Santacruz Silver Mining Ltd. (LSX:A41S50) generated €277.89 million in revenue last year. The Zimapan segment was the top-performing segment, contributing €88.75 million, an increase from €75.12 million the previous year. Geographically, Bolivia was the largest contributor to revenue, accounting for €194.01 million.

FA Q2 Deep Dive: AI-Driven Solutions, Enterprise Wins, and Guidance Raise Shape Outlook

FA Q2 Deep Dive: AI-Driven Solutions, Enterprise Wins, and Guidance Raise Shape Outlook Background screening provider First Advantage (NASDAQ:FA) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 14.9% year on year to $448.8 million. The company's full-year revenue guidance …

Atlanta Electricals Schedules Investor and Analyst Meetings in Mumbai

Sei Investments Co. Buys 45,608 Shares of First Advantage Co. $FA

First Advantage Co. $FA Shares Acquired by Quantinno Capital Management LP

NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher

NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter's revenue guidance …

Cantabil Retail Standalone June 2026 Net Sales at Rs 178.82 crore, up 12.7% Y-o-Y

Santana Minerals (ASX:SMI) Advances Bendigo-Ophir Gold Project Toward December Approval

United Plantations Berhad Reports Production Results for the Month and Year to Date Ended July 2026

ENANTA PHARMACEUTICALS ($ENTA) Releases Q3 2026 Earnings

Vedanta Aluminium, Vedanta Power in focus: Here is why demerged stocks could see action

How Investors Are Reacting To Quanta Services (PWR) $2 Billion Long‑Dated Debt Raise And Upgraded Outlook